儿童肾母细胞瘤诊疗专家共识

2020-07-30 中华医学会小儿外科学分会 中华小儿外科杂志.2020,41(7):585-590.

过去50年中,在外科手术、化疗、放疗等多学科协作努力下,发达国家肾母细胞瘤的5年总体生存率可以超过90%,然而一些特殊类型的患儿,如病理间变型、肿瘤复发的患儿,还有双侧肾母细胞瘤和单侧高风险的肾母细胞

中文标题:

儿童肾母细胞瘤诊疗专家共识

发布日期:

2020-07-30

简要介绍:

过去50年中,在外科手术、化疗、放疗等多学科协作努力下,发达国家肾母细胞瘤的5年总体生存率可以超过90%,然而一些特殊类型的患儿,如病理间变型、肿瘤复发的患儿,还有双侧肾母细胞瘤和单侧高风险的肾母细胞瘤患儿的无事件生存率(eventfreesurvival,EFS)仍然不高,而且存在严重的远期并症。2017年中国抗癌协会小儿肿瘤专业委员会对儿童肾母细胞瘤的诊断和治疗发表了共识,在此基础上中华医学会小儿外科学分会泌尿外科学组专家共同参加专题研讨会,结合各自的临床经验和研究成果,参考国内外相关文献,主要就肾母细胞瘤的诊断和治疗.特别是外科手术相关的一些问题达成以下共识。

下载附件:

(因为版权问题,不支持下载)

评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1016213, encodeId=9d3010162133b, content=好东西,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56da81912, createdName=xsxmin, createdTime=Fri Sep 10 05:48:56 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012819, encodeId=ef28101281928, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a675585115, createdName=ms9000000474829914, createdTime=Mon Aug 30 13:22:19 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007108, encodeId=a988100e108d2, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Wed Aug 11 22:41:31 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965413, encodeId=9ba99654136f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210514/62321148b3e54a0bb2162e4b55b04e63/9a4f837d181340909c89e267fa6eb8ac.jpg, createdBy=82165314151, createdName=武志祥, createdTime=Fri May 14 05:08:59 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919611, encodeId=1cd591961146, content=好东西,学习共享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10702294153, createdName=121f181dm78暂无昵称, createdTime=Mon Jan 25 08:23:57 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-09-10 xsxmin

    好东西,学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1016213, encodeId=9d3010162133b, content=好东西,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56da81912, createdName=xsxmin, createdTime=Fri Sep 10 05:48:56 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012819, encodeId=ef28101281928, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a675585115, createdName=ms9000000474829914, createdTime=Mon Aug 30 13:22:19 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007108, encodeId=a988100e108d2, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Wed Aug 11 22:41:31 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965413, encodeId=9ba99654136f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210514/62321148b3e54a0bb2162e4b55b04e63/9a4f837d181340909c89e267fa6eb8ac.jpg, createdBy=82165314151, createdName=武志祥, createdTime=Fri May 14 05:08:59 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919611, encodeId=1cd591961146, content=好东西,学习共享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10702294153, createdName=121f181dm78暂无昵称, createdTime=Mon Jan 25 08:23:57 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-08-30 ms9000000474829914

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1016213, encodeId=9d3010162133b, content=好东西,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56da81912, createdName=xsxmin, createdTime=Fri Sep 10 05:48:56 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012819, encodeId=ef28101281928, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a675585115, createdName=ms9000000474829914, createdTime=Mon Aug 30 13:22:19 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007108, encodeId=a988100e108d2, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Wed Aug 11 22:41:31 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965413, encodeId=9ba99654136f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210514/62321148b3e54a0bb2162e4b55b04e63/9a4f837d181340909c89e267fa6eb8ac.jpg, createdBy=82165314151, createdName=武志祥, createdTime=Fri May 14 05:08:59 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919611, encodeId=1cd591961146, content=好东西,学习共享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10702294153, createdName=121f181dm78暂无昵称, createdTime=Mon Jan 25 08:23:57 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-08-11 120d5e71m96(暂无昵称)

    获益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1016213, encodeId=9d3010162133b, content=好东西,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56da81912, createdName=xsxmin, createdTime=Fri Sep 10 05:48:56 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012819, encodeId=ef28101281928, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a675585115, createdName=ms9000000474829914, createdTime=Mon Aug 30 13:22:19 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007108, encodeId=a988100e108d2, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Wed Aug 11 22:41:31 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965413, encodeId=9ba99654136f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210514/62321148b3e54a0bb2162e4b55b04e63/9a4f837d181340909c89e267fa6eb8ac.jpg, createdBy=82165314151, createdName=武志祥, createdTime=Fri May 14 05:08:59 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919611, encodeId=1cd591961146, content=好东西,学习共享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10702294153, createdName=121f181dm78暂无昵称, createdTime=Mon Jan 25 08:23:57 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-05-14 武志祥

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1016213, encodeId=9d3010162133b, content=好东西,学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56da81912, createdName=xsxmin, createdTime=Fri Sep 10 05:48:56 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012819, encodeId=ef28101281928, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a675585115, createdName=ms9000000474829914, createdTime=Mon Aug 30 13:22:19 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007108, encodeId=a988100e108d2, content=获益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=258a2211002, createdName=120d5e71m96(暂无昵称), createdTime=Wed Aug 11 22:41:31 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965413, encodeId=9ba99654136f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210514/62321148b3e54a0bb2162e4b55b04e63/9a4f837d181340909c89e267fa6eb8ac.jpg, createdBy=82165314151, createdName=武志祥, createdTime=Fri May 14 05:08:59 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919611, encodeId=1cd591961146, content=好东西,学习共享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10702294153, createdName=121f181dm78暂无昵称, createdTime=Mon Jan 25 08:23:57 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-01-25 121f181dm78暂无昵称

    好东西,学习共享

    0

拓展阅读

儿童肾母细胞瘤病理诊断共识

北京儿童医院集团病理协作组 · 2017-03-20

儿童肾母细胞瘤诊断治疗建议(CCCG-WT-2016)

中国抗癌协会小儿肿瘤专业委员会 · 2017-02-20

儿童肾母细胞瘤诊疗规范(2019 年版)

中华人民共和国国家卫生健康委员会 · 2019-09-05

2022 UICC 白皮书:肾母细胞瘤儿科患者肿瘤生育学

国际抗癌联盟(UICC,Union for International Cancer Control) · 2022-03-28